Overview

  • Product name
    Anti-PTEN antibody [SP218] - C-terminal
    See all PTEN primary antibodies
  • Description
    Rabbit monoclonal [SP218] to PTEN - C-terminal
  • Host species
    Rabbit
  • Tested applications
    Suitable for: Flow Cyt, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Dog
  • Immunogen

    Synthetic peptide within Human PTEN aa 350 to the C-terminus (C terminal). The exact sequence is proprietary.
    Database link: P60484

  • Positive control
    • WB: HeLa whole cell lysate (ab150035). Flow Cyt: A431 and MCF7 cells IHC-P: Human prostate adenocarcinoma and colon adenocarcinoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab228466 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/200 - 1/240.
IHC-P 1/200.

Boil tissue section in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at room temperature for 20 min.

Primary antibody incubation for 10 minutes at room temperature.

WB 1/400. Predicted molecular weight: 47 kDa.

Target

  • Function
    Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
    Isoform alpha: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1.
  • Tissue specificity
    Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
  • Involvement in disease
    Cowden syndrome 1
    Lhermitte-Duclos disease
    Bannayan-Riley-Ruvalcaba syndrome
    Squamous cell carcinoma of the head and neck
    Endometrial cancer
    PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
    Glioma 2
    VACTERL association with hydrocephalus
    Prostate cancer
    Macrocephaly/autism syndrome
    A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
  • Sequence similarities
    Contains 1 C2 tensin-type domain.
    Contains 1 phosphatase tensin-type domain.
  • Domain
    The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
  • Post-translational
    modifications
    Constitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
    Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.
  • Cellular localization
    Secreted. May be secreted via a classical signal peptide and reenter into cells with the help of a poly-Arg motif and Cytoplasm. Nucleus. Nucleus, PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.
  • Information by UniProt
  • Database links
  • Alternative names
    • 10q23del antibody
    • BZS antibody
    • DEC antibody
    • GLM2 antibody
    • MGC11227 antibody
    • MHAM antibody
    • MMAC1 antibody
    • MMAC1 phosphatase and tensin homolog deleted on chromosome 10 antibody
    • Mutated in multiple advanced cancers 1 antibody
    • Phosphatase and tensin homolog antibody
    • Phosphatase and tensin like protein antibody
    • Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN antibody
    • Pten antibody
    • PTEN_HUMAN antibody
    • PTEN1 antibody
    • TEP1 antibody
    see all

Images

  • Flow Cytometry analysis of MCF7 (human breast adenocarcinoma epithelial cell) cells labeling PTEN with purified ab228466 at 1/240 dilution (1.01 µg/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000 dilution. Isotype control - Rabbit monoclonal IgG (ab172730) / Black. Unlabeled control - Unlabelled cells / blue.

  • Anti-PTEN antibody [SP218] - C-terminal (ab228466) at 1/400 dilution + HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate

    Predicted band size: 47 kDa

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Flow cytometric analysis of A431 (human epidermoid carcinoma cell line) cells  labeling PTEN with ab228466 at 1/200 dilution (green) compared with a negative control rabbit IgG (blue). 

  • Cancer cells from prostate adenocarcinoma (panel A) and colon adenocarcinoma (panel D) show total loss or diminished expression of PTEN when SP218 is used. In contrast, nuclear staining (panel B and C, arrows) in cancer cells is present for clones D4.3 and 138G6. Diffuse cytoplasmic and stromal staining are prominent for clones D4.3 and 138G6. But interestingly, the stromal cell components (fibroblasts, lymphocytes, and endothelial cells) are stained with similar intensities across all images. This suggests that there is non-specific staining in stromal and cancer area with clones D4.3 and 138G6 when compared with SP218.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human colon adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

  • Formalin-fixed, paraffin-embedded human prostate adenocarcinoma tissue stained for PTEN using ab228466 at 1/200 dilution in immunohistochemical analysis.

Protocols

References

This product has been referenced in:
  • Nunes M  et al. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Cancer Res 75:1560-6 (2015). Read more (PubMed: 25712343) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab228466.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up